Grace Therapeutics, Inc.
GRCE· Nasdaq
GRCEGrace Therapeutics, Inc.
Filed Aug 9, 2024 · 10-Q · 40 days after period end · 0000950170-24-094348
| Metric | Q1 2025 | Q1 2024 | Q1 2023 | Q1 2022 |
|---|---|---|---|---|
| Net Income | -$2.62M | -$4.02M | -$4.52M | -$3.12M |
| EPS Diluted | -$0.24 | -$0.54 | -$0.61 | -$0.12 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Grace Therapeutics, Inc. · CIK 1444192 · Engraved from SEC EDGAR
ended Jun 30, 2024 · filed Aug 9, 2024 · 40 d after period end
